Abstract:VPAC1 encodes G-protein–coupled receptors expressed on all breast cancer (BC) cells at the onset of the disease, but not on benign lesions. Our extensive preclinical studies have shown that 64Cu-TP3805 has a high affinity for VPAC1, is stable in vivo, and has the ability to distinguish spontaneously grown malignant BC masses from benign lesions. Our long-term goal is to develop 64Cu-TP3805 as an agent to perform in vivo histology, to distinguish malignant lesions from benign masses noninvasively and thereby avoid patient morbidity and the excess economic costs of benign biopsies. Methods: 18F-FDG obtained commercially served as a control. 64Cu-TP3805 was prepared using a sterile kit containing 20 μg of TP3805. Radiochemical purity and sterility were examined. Nineteen consenting women with histologically proven BC were given 370 MBq of 18F-FDG. One hour later, 6 of these patients were imaged with PET/CT and 13 with positron emission mammography (PEM). Two to 7 d later, 6 PET/CT patients received 111 MBq (±10%) (n = 2), 127 MBq (±10%) (n = 2), or 148 MBq (±10%) (n = 2) of 64Cu-TP3805 and were imaged 2 and 4 h later. Thirteen PEM patients received 148 MBq (±10%) of 64Cu-TP3805 and were imaged 15 min, 1 h, 2 h, and 4 h later. Standardized uptake value (SUV) was calculated for PET/CT patients, and PUV/BGV (PEM uptake value/background value) was calculated for PEM patients. Tumor volume was also calculated. Results: The radiochemical purity of 64Cu-TP3805 was 97% ± 2%, and specific activity was 44.4 GBq (1.2 Ci)/μmol. In 19 patients, a total of 24 lesions were imaged (15 invasive ductal carcinoma, 1 high-grade mammary carcinoma, 3 lobular carcinoma, 1 invasive papilloma, and 4 sentinel lymph nodes). All lesions were unequivocally detected by 64Cu-TP3805 and by 18F-FDG. The average tumor volume as determined by PET/CT with 64Cu-TP3805 was 90.6% ± 16.1% of that with 18F-FDG PET/CT, and the average SUV was 92% ± 26.4% of that with 18F-FDG. For PEM, the tumor volume with 64Cu-TP3805 was 113% ± 37% of that with 18F-FDG and the PUV/BGV ratio was 97.7% ± 24.5% of that with 18F-FDG. Conclusion: 64Cu-TP3805 is worthy of further investigation in patients requiring biopsy of suggestive imaging findings, to further evaluate its ability to distinguish malignant lesions from benign masses noninvasively.

First-in-human Evaluation of Safety and Dosimetry of [64Cu]FBP8: A fibrin-binding PET Probe

Dosimetry of [64Cu]FBP8: a fibrin-binding PET probe

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin

Biodistribution, Dosimetry, and Pharmacokinetics of 68Ga-CBP8: A Type I Collagen-Targeted PET Probe

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Biodistribution and Radiation Dosimetry of the Enterobacteriaceae -Specific Imaging Probe [ 18 F]Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers

First-in-Human Evaluation Of18f-Pf-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B

Radiosynthesis and First-In-Human PET/MRI Evaluation with Clinical-Grade [18F]FTC-146

Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis

Biodistribution and radiation dosimetry of D-isomer of 4-borono-2-[18F]fluoro-phenylalanine: A comparative PET/CT study with L-isomer in healthy human volunteers

Radiofluorinated probe for PET imaging of fatty acid binding protein 4 in cancer

Synthesis and Biological Evaluation of a Radiolabeled PET (Positron Emission Tomography) Probe for Visualization of In Vivo α-Fucosidase Expression

Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy

Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [68Ga]ga-Fapi-fuscc-ii.

Synthesis and pharmacological evaluation of [18F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971

Synthesis and Radiolabeling of (64)Cu-Labeled 2-Nitroimidazole Derivative (64)Cu-Bms2p2 for Hypoxia Imaging.

Preclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study

A radiofluorinated divalent cystine knot peptide for tumor PET imaging.

Development of [ 64 Cu]Cu-BPAMD for PET imaging of bone metastases